远大医药集团是一家科技创新型国际化医药企业，集制药科技、核药抗肿瘤诊疗及心脑血管精准介入诊疗科技、生物科技于一体。

远大医药集团

Activ Surgical is involved in the development of surgical technologies and tools. Self-described as innovative, it focuses on enhancing surgical procedures through its technological offerings.

Activ Surgical

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

Metric
Company Name	远大医药集团	Activ Surgical	CanSino Biologics Inc.
Symbol			6.18K
MSH ID	CN:GRANDPHARMA	COM:ACTIVSURGICAL	COM:CANSINOTECH
Market	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Pharmaceuticals	Medical Devices	Drug Manufacturers - Specialty & Generic
Country	CN	US	CN
Stage
Employee Count			1.49K
Website	grandpharma.cn	activsurgical.com	cansinotech.com
LinkedIn			cansino-biotechnology-inc.
Founders

Metric
Market Cap			833.96M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue			49.12M
Revenue (LTM)
Revenue (NTM)
Gross Profit			-61.04M
EBITDA			-203.86M
Operating Income			-236.92M
Net Income			-203.94M
EPS			-0.83
Diluted EPS			-0.83
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.14
Operating Profit Margin			-0.86
EBITDA Margin			-4.15
Net Profit Margin			-1.42
Return on Equity			-0.16
Return on Assets			-0.11
Return on Capital Employed			-0.08

GRAN

CN:GRANDPHARMA

远大医药集团

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			20.35
EV Multiple			-3.00

Metric
Days Sales Outstanding			485.87
Days Payables Outstanding			170.20
Days Inventory Outstanding			251.49
Operating Cycle			815.83
Cash Conversion Cycle			770.86
Asset Turnover			0.07

Metric
Operating Cash Flow			-124.92M
Free Cash Flow			-208.89M
Cash Flow to Debt			-0.12
Operating Cash Flow/Sales			-0.43
Free Cash Flow Yield			-0.25

Metric
Cash & Equivalents			388.10M
Accounts Receivable			36.58M
Inventory			48.53M
Goodwill
Debt to Capitalization			0.34
Debt to Assets			0.21
Current Ratio			2.24
Quick Ratio			2.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue			1.04
SG&A to Revenue			0.34